［1］SHOAIB Z,FAN TM,IRUDAYARAJ JMK.Osteosarcoma mechanobiology and therapeutic targets［J］.Br J Pharmacol,2022,179(2):201-217.
［2］CHEN C,XIE L,REN T,et al.Immunotherapy for osteosarcoma:Fundamental mechanism,rationale,and recent breakthroughs［J］.Cancer Lett,2021,500:1-10.
［3］YOSHIDA A.Osteosarcoma:old and new challenges［J］.Surg Pathol Clin,2021,14(4):567-583.
［4］NIRAL BK,YAMAMICHI T,YUSTEIN JT.Deciphering the signaling mechanisms of osteosarcoma tumorigenesis［J］.Int J Mol Sci,2023,24(14):11367.
［5］BELAYNEH R,FOURMAN MS,BHOGAL S,et al.Update on osteosarcoma［J］.Curr Oncol Rep,2021,23(6):71.
［6］GILL J,GORLICK R.Advancing therapy for osteosarcoma［J］.Nat Rev Clin Oncol,2021,18: 609-624.
［7］LIU Y,FANG C,LUO J,et al.Traditional chinese medicine for cancer treatment［J］.Am J Chin Med,2024,52(3):583-604.
［8］MOAZAMIYANFAR R,REZAEI S,ALIASHRAFZADEH H,et al.Nobiletin in cancer therapy;mechanisms and therapy perspectives［J］.Curr Pharm Des,2023,29(22):1713-1728.
［9］MELTZER PS,HELMAN LJ.New horizons in the treatment of osteosarcoma［J］.N Engl J Med,2021,385(22):2066-2076.
［10］HARRIS MA,HAWKINS CJ.Recent and ongoing research into metastatic osteosarcoma treatments［J］.Int J Mol Sci,2022,23(7):3817.
［11］LI N,ZHANG Z,JIANG G,et al.Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway［J］.Front Biosci (Landmark Ed),2019,24:303-312.
［12］WU Y,LI Q,LV LL,et al.Nobiletin inhibits breast cancer cell migration and invasion by suppressing the IL-6-induced ERK-STAT and JNK-c-JUN pathways［J］.Phytomedicine,2023,110:154610.
［13］XU Z,WU D,FU D,et al.Nobiletin inhibits viability of human renal carcinoma cells via the JAK2/STAT3 and PI3K/Akt pathway［J］.Cell Mol Biol(Noisyle-grand),2020,66(5):199-203.
［14］RATHINASWAMY MK,JENKINS ML,DUEWELL BR,et al.Molecular basis for differential activation of p101 and p84 complexes of PI3Kγ by Ras and GPCRs［J］.Cell Rep,2023,42(3):112172.
［15］CHANG J,HONG L,LIU Y,et al.Targeting PIK3CG in combination with paclitaxel as a potential therapeutic regimen in claudin-low breast cancer［J］.Cancer Manag Res,2020,12:2641-2651.
［16］KANEDA MM,MESSER KS,RALAINIRINA N,et al.PI3Kgamma is a molecular switch that controls immune suppression［J］.Nature,2016,539(7629):437-442.
［17］CHUNG WC,ZHOU X,ATFI A,et al.PIK3CG is a potential therapeutic target in androgen receptor-indifferent metastatic prostate cancer［J］.Am J Pathol,2020,190(11):2194-2202.
［18］DI X,PAN Y,YAN J,et al.Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway［J］.Heliyon,2023,10(1):e23165.
［19］HUANG B,DING J,GUO H,et al.SIRT3 egulates the ROS-FPR1/HIF-1α axis under hypoxic conditions to influence lung cancer progression［J］.Cell Biochem Biophys,2023,81(4):813-821.
［20］SZTUPINSEKI Z,LE NAOUR J,VACCHELLI E,et al.A major genetic accelerator of cancer diagnosis:rs867228 in FPR1［J］.Oncoimmunology,2021,10(1):1859064.
［21］MORRIS S,VACHANI A,PASS HI,et al.Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer［J］.Int J Cancer,2018,142(11):2355-2362.
［22］LESLIE J,MILLAR BJ,DEL CARPIO PONS A,et al.FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis［J］.JCI Insight,2020,5(4):e125937.
［23］CARBONNIER V,LE NAOUR J,BACHELOT T,et al.Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer［J］.Oncoimmunology,2023,12(1):2189823.
［24］HUANG B,GUO H,DING J,et al.Inhibition of formyl peptide receptor 1 activity suppresses tumorigenicity in vivo and attenuates the invasion and migration of lung adenocarcinoma cells under hypoxic conditions in vitro［J］.Ann Transl Med,2020,8(18):1174.
［25］TSAI ML,LEE CH,HUANG LC,et al.CRISPR-mediated knockout of VEGFR2/KDR inhibits cell growth in a squamous thyroid cancer cell line［J］.FEBS Open Bio,2022,12(5):993-1005.
［26］ZHANG L,NIU X,BI Y,et al.Potential role of targeting KDR and proteasome inhibitors in the therapy of esophageal squamous cell carcinoma［J］.Technol Cancer Res Treat,2020,19:1533033820948060.